IP Library Granted Patent US 9,192,580
Granted Patent B2
US 9,192,580 · App. 10/685,728 · Granted Nov 24, 2015

Fast-dispersing dosage forms containing fish gelatin

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,192,580
App. No.
10/685,728
Granted
Nov 24, 2015
Kind
B2
Abstract

The invention disclosed herein relates to a pharmaceutical composition comprising a carrier and an active ingredient, wherein the carrier is fish gelatin and the composition is a fast-dispersing dosage form designed to release the active ingredient rapidly on contact with a fluid. In one embodiment, the composition is designed for oral administration and releases the active ingredient rapidly in the oral cavity on contact with saliva. The fish gelatin can be obtained from cold water fish sources and is preferably the non-gelling, non-hydrolyzed form. A process for preparing such a composition and a method of using fish gelatin in a fast dispersing dosage form are also provided.

Claims (5)

1. A pharmaceutical composition in an oral solid molded fast-dispersing dosage form comprising an active ingredient and a non-hydrolyzed, non-gelling fish gelatin carrier which releases the active ingredient, wherein said composition disintegrates within 1 to 60 seconds of being placed in contact with fluid, and wherein said dosage form comprises a network of the active ingredient and the non-hydrolyzed, non-gelling fish gelatin carrier prepared by the process of subliming solvent from an admixture in the solid state in which the admixture comprises the active ingredient, the non-hydrolyzed, non-gelling fish gelatin carrier and a solvent.

2. The pharmaceutical composition according to claim 1 , wherein the active ingredient is present in an amount ranging from about 0.2% to about 95% by weight of the composition in dried dosage form.

3. The pharmaceutical composition according to claim 2 , wherein the active ingredient is present in an amount ranging from about 1% to about 20% by weight of the composition in dried dosage form.

4. The pharmaceutical composition according to claim 1 , wherein the non-hydrolyzed, non-gelling fish gelatin is spray-dried non-hydrolyzed, non-gelling fish gelatin.

5. The pharmaceutical composition according to claim 1 further comprising an additional ingredient selected from the group consisting of matrix forming agents, sugars, cyclic sugars, amino acids, preservatives, surfactants, viscosity enhancers, coloring agents, flavoring agents, pH modifiers, sweeteners, taste-masking agents, and combinations thereof.

Assignments (4)
RELEASE OF SECURITY INTEREST IN PATENT COLLATERAL (019323/0302) Recorded Dec 19, 2024
From: JPMORGAN CHASE BANK, N.A.
To: CATALENT PHARMA SOLUTIONS, LLC; R.P. SCHERER TECHNOLOGIES, INC.; R.P. SCHERER TECHNOLOGIES, LLC; R.P. SCHERER CORPORATION
Reel/Frame 069750/0933 →
NOTICE OF SUCCESSION OF AGENCY Recorded May 17, 2019
From: MORGAN STANLEY SENIOR FUNDING, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 049217/0981 →
CHANGE OF NAME Recorded Jul 24, 2007
From: CARDINAL HEALTH 400, INC.; CARDINAL HEALTH 406, LLC; CARDINAL HEALTH 409, INC.; CARDINAL HEALTH 421, INC.; CARDINAL HEALTH PTS, LLC
To: CATALENT USA WOODSTOCK, INC.; CATALENT USA PACKAGING, LLC; CATALENT PHARMA SOLUTIONS, INC.; CATALENT USA PAINTBALL, INC.; CATALENT PHARMA SOLUTIONS, LLC
Reel/Frame 019588/0622 →
SECURITY AGREEMENT Recorded May 22, 2007
From: PTS ACQUISITION CORP.; PTS INTERMEDIATE HOLDINGS LLC; CARDINAL HEALTH 400, INC.; CARDINAL HEALTH 406, LLC; CARDINAL HEALTH 421, INC.; CARDINAL HEALTH PTS, LLC; R.P. SCHERER TECHNOLOGIES, INC.; GLACIER CORPORATION; CARDINAL HEALTH 409, INC.
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 019323/0302 →